Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs Smith & Nephew plc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9, while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals.
| SJNK | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $25.63 | $38.70 |
52-Week Low | $24.75 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK trades at $24.92 with no change over the past 24 hours, reflecting stability amid a bearish technical signal from moving averages. The ETF maintains a neutral stance in oscillators, with RSI levels indicating neither overbought nor oversold conditions. Recent corporate actions include scheduled dividend payments, with H2-26 set at $0.15 per share. Institutional activity shows Balefire LLC reduced its stake by 74.7% in the latest quarter, as per SEC filings dated 2026-07-21.
The outlook for SJNK is cautious due to bearish technical indicators and negative sentiment from analysts, who rate it SELL citing exhausted tailwinds from falling yields. Risks include high sensitivity to interest rate changes and credit spread volatility. Investment opportunity lies in its high-yield bond focus, but current conditions suggest limited near-term upside amid macroeconomic uncertainties.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
